EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Enhancing activity of FcαRI-bispecific antibodies using glycoengineering

Céline A N Sewnath iD, Timon Damelang, Arthur E H Bentlage iD, Luuk Ten Kroode, Cornelis W Tuk, Remco Visser, Manfred Wuhrer iD, Julie Van Coillie, Theo Rispens, Marjolein van Egmond, Gestur Vidarsson iD

The Journal of Immunology · 01.06.2025 · 214 (6) · 1261-1271

DOI: 10.1093/jimmun/vkaf027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.03.2025. Verfasst von Céline A N Sewnath und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Cell Biology and Immunology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Killer Cells, Natural, Antibodies, Bispecific, Receptors, Fc. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KWF Dutch Cancer Society, Name of Grant Holder: Prof. Dr Marjolein van Egmond.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Macrophages and natural killer (NK) cells can effectively kill tumor cells in the presence of anti-cancer IgG monoclonal antibodies (mAbs), but neutrophils are less effective. We previously showed that IgG1 bispecific antibodies (BsAb), which target the IgA Fc receptor (FcαRI, CD89) and a tumor associated antigen induce effective neutrophil recruitment and tumor cell killing in vivo. Here we investigated if the efficacy of an anti-EGFR (CetuximAb)/FcαRI-bispecific antibody could be further improved by implementing glycoengineering of the IgG-Fc, aimed at increasing FcγRIIIa/b binding and/or complement activity. Fc afucosylation was introduced to enhance antibody-dependent cellular cytotoxicity (ADCC) by FcγRIIIa on NK/macrophages, which can also reduce neutrophil-mediated ADCC through their GPI-linked FcγRIIIb. Fc galactylation was found to enhance antibody hexamerization and thereby complement dependent cytotoxicity (CDC). Low fucosylated BsAbs moderately increased NK cell-mediated tumor cell killing, but did not affect neutrophil-mediated tumor cell killing nor phagocytosis by macrophages. Glycoengineering of these EGFR-specific BsAb, which normally are devoid of CDC-activity, did not enable their complement activities. In conclusion, glycoengineered FcαRI BsAbs increased ADCC by NK cells but had little effect on neutrophil or macrophage mediated tumor killing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Killer Cells, NaturalAntibodies, BispecificReceptors, FcHumansAntibody-Dependent Cell CytotoxicityReceptors, IgGNeutrophilsMacrophagesCell Line, TumorErbB ReceptorsProtein EngineeringAnimalsCetuximabImmunoglobulin GGlycosylationMicePhagocytosisImmunoglobulin Fc FragmentsAntigens, CD

Stichwörter der Autor:innen

bispecific antibodiescytotoxic effector cellsglycomodificationtumor cells

Substanzen

Antibodies, BispecificReceptors, IgGReceptors, FcFc(alpha) receptorErbB ReceptorsCetuximabImmunoglobulin GFCGR3A protein, humanImmunoglobulin Fc FragmentsAntigens, CD

Autor:innen und Institutionen

  • Department of Molecular Cell Biology and Immunology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Cancer Center Amsterdam, Cancer Biology and Immunology Program, Amsterdam, The Netherlands.
  • Amsterdam institute for Infection and Immunity, Cancer Immunology Program, Amsterdam, The Netherlands.
  • Department of Immunopathology, Sanquin Research, Amsterdam, Netherlands.
  • Department of Biomolecular Mass Spectrometry and Proteomics, Utrecht Institute for Pharmaceutical Sciences and Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, The Netherlands.
  • Department of Proteomics and Metabolomics, Leids Universitair Medisch Centrum (LUMC), LUMC, The Netherlands.

ORCID-Profile: Céline A N Sewnath, Arthur E H Bentlage, Manfred Wuhrer, Gestur Vidarsson

Förderung

  • KWF Dutch Cancer Society
  • Name of Grant Holder: Prof. Dr Marjolein van Egmond

Zitieren

APA

Sewnath, C. A. N., Damelang, T., Bentlage, A. E. H., Ten Kroode, L., Tuk, C. W., Visser, R., Wuhrer, M., Van Coillie, J., Rispens, T., van Egmond, M., & Vidarsson, G. (2025). Enhancing activity of FcαRI-bispecific antibodies using glycoengineering. The Journal of Immunology, 214(6), 1261-1271. https://doi.org/10.1093/jimmun/vkaf027

Vancouver

Sewnath CAN, Damelang T, Bentlage AEH, Ten Kroode L, Tuk CW, Visser R, et al. Enhancing activity of FcαRI-bispecific antibodies using glycoengineering. The Journal of Immunology. 2025;214(6):1261-1271. doi:10.1093/jimmun/vkaf027

BibTeX
@article{Sewnath2025,
  author = {Sewnath, Céline A N and Damelang, Timon and Bentlage, Arthur E H and Ten Kroode, Luuk and Tuk, Cornelis W and Visser, Remco and Wuhrer, Manfred and Van Coillie, Julie and Rispens, Theo and van Egmond, Marjolein and Vidarsson, Gestur},
  title = {Enhancing activity of FcαRI-bispecific antibodies using glycoengineering},
  journal = {The Journal of Immunology},
  year = {2025},
  volume = {214},
  number = {6},
  pages = {1261--1271},
  doi = {10.1093/jimmun/vkaf027}
}
Kostenlos starten →